On Tuesday, MaxCyte Inc (NASDAQ: MXCT) opened higher 3.24% from the last session, before settling in for the closing price of $4.94. Price fluctuations for MXCT have ranged from $3.16 to $5.32 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 18.61% over the last five years. Company’s average yearly earnings per share was noted -11.32% at the time writing. With a float of $97.35 million, this company’s outstanding shares have now reached $105.30 million.
The firm has a total of 143 workers. Let’s measure their productivity. In terms of profitability, gross margin is 79.04%, operating margin of -101.56%, and the pretax margin is -78.36%.
MaxCyte Inc (MXCT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of MaxCyte Inc is 7.71%, while institutional ownership is 67.74%. The most recent insider transaction that took place on Jan 13 ’25, was worth 20,272. In this transaction GENERAL COUNSEL of this company sold 4,466 shares at a rate of $4.54, taking the stock ownership to the 41,447 shares. Before that another transaction happened on Dec 26 ’24, when Company’s Director sold 3,000 for $4.01, making the entire transaction worth $12,021. This insider now owns 141,950 shares in total.
MaxCyte Inc (MXCT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.32% per share during the next fiscal year.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Check out the current performance indicators for MaxCyte Inc (MXCT). In the past quarter, the stock posted a quick ratio of 9.22. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.34, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.38 in one year’s time.
Technical Analysis of MaxCyte Inc (MXCT)
Analysing the last 5-days average volume posted by the [MaxCyte Inc, MXCT], we can find that recorded value of 0.78 million was better than the volume posted last year of 0.69 million. As of the previous 9 days, the stock’s Stochastic %D was 86.40%. Additionally, its Average True Range was 0.30.
During the past 100 days, MaxCyte Inc’s (MXCT) raw stochastic average was set at 95.09%, which indicates a significant increase from 91.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 64.49% in the past 14 days, which was higher than the 57.66% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.00, while its 200-day Moving Average is $4.13. Now, the first resistance to watch is $5.22. This is followed by the second major resistance level at $5.33. The third major resistance level sits at $5.47. If the price goes on to break the first support level at $4.97, it is likely to go to the next support level at $4.83. Now, if the price goes above the second support level, the third support stands at $4.72.
MaxCyte Inc (NASDAQ: MXCT) Key Stats
There are currently 105,711K shares outstanding in the company with a market cap of 537.96 million. Presently, the company’s annual sales total 41,290 K according to its annual income of -37,920 K. Last quarter, the company’s sales amounted to 8,160 K and its income totaled -11,560 K.
